Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company’s Board of Directors
2012-01-03
- Accera, Inc., announced today that Holger Kunze has been appointed to the position of Chief Executive Officer and as a member of the company's Board of Directors (BoD). Concurrently, Sven Thormahlen, Ph.D., has also been appointed as a member of Accera's BoD.
Accera: novel therapies and video
2011-08-05
-
Accera is uniquely targeting metabolic defects in neurodegenerative disorders for the treatment of Alzheimer's disease. Axona® is a prescription medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease. The human brain relies almost exclusively on glucose as a source of energy. Research shows that, in Alzheimer's disease patients, there is a dramatic drop in the brain's ability to metabolize glucose.
-
Axona is a medical food regulated by the FDA that addresses energy deficiencies in the brain by providing an alternative source of energy. This is very well described in the video link.
Holger Kunze, Accera:"Working with Inventages has been very productive."
